Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBP-398 plus sotorasib in KRAS G12C-mutant advanced solid tumors
NL-OMON59111Phase 1Completed
- Sponsor
- Navire Pharma
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BMS-986466 and sotorasib in Nonhematologic neoplasms and non-small cell lung cancer (NSCLC), sponsored by Navire Pharma. Started Oct 2023; status: completed.
02
Drugs
BMS-986466sotorasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON59111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59111.